Zobrazeno 1 - 10
of 255
pro vyhledávání: '"11"'
Autor:
Sho Ikeda, Kentaro Narita, Yuto Takahashi, Daisuke Miura, Naoto Takahashi, Takafumi Tsushima, Akihiro Kitadate, Toshiki Terao, Kosei Matsue, Masami Takeuchi
Publikováno v:
Cancer Science
CD38 expression on myeloma cells is a critical factor affecting the early response to the anti‐CD38 antibody daratumumab. However, factors affecting CD38 expression in untreated multiple myeloma are not fully elucidated. In this study, we found tha
Autor:
Kerry L. Cox, Graham Packham, Mark S. Cragg, Stuart Blakemore, Robert J. Oldham, Anna H. Turaj, Francesco Forconi, Matthew J. Carter, Stacey Tannheimer, Lekh N. Dahal
Publikováno v:
Leukemia
Introduction: Phosphatidylinositol-3-kinase δ (PI3Kδ)-signaling provides key maintenance, proliferation, and survival cues during both normal and malignant B-lymphocyte development. Consequently, isoform-selective PI3Kδ inhibitors (PI3Kδi) have g
Autor:
Yue-Peng Wang, Hong Wang, Wei-Ping Xu, Yi-Gang Li, Jie Chen, Si-Si Wei, Hui Joyce Li, Yun-Qing Mei
Publikováno v:
Oncotarget
CD22 is a surface immunoglobulin implicated in negative regulation of B cell receptor (BCR) signaling; particularly inhibiting intracellular Ca2+ (Ca2+i)signals. Its cytoplasmic tail contains six tyrosine residues (Y773/Y783/Y817/Y828/Y843/Y863, desi
Autor:
William P. McGuire, Andrew Poklepovic, Jane L. Roberts, Mehrad Tavallai, Paul Dent, Laurence Booth
Publikováno v:
Oncotarget
// Mehrad Tavallai 1 , Laurence Booth 1 , Jane L. Roberts 1 , William P. McGuire 2 , Andrew Poklepovic 2 and Paul Dent 1 1 Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA 2 Department of Medicine,
Autor:
Li Chen, Yuan Zhang, Jun Liu, Wei Tian, Hong‑Yun Fu, Jun He, Jian Li, Cong Yuan, Xiao‑Long Lin, Tian‑Ping Tan, Shao‑Jian Wu, Shan Yu, Mi‑Hua Liu, Yu‑Dan Chen
Publikováno v:
Molecular Medicine Reports. 13:1689-1694
Resveratrol is a polyphenolic compound found in wine, which is mainly produced by the grapevine and exerts chemopreventive effects against hepatocellular carcinoma. However, the underlying molecular mechanisms have remained to be fully elucidated. Th
Autor:
Maja T. Tomicic, Dorthe Aasland, Ruth Meise, Bernd Kaina, Oliver H. Krämer, Nancy Berte, Rebekka Kitzinger, Markus Christmann
Publikováno v:
Oncotarget
// Maja T. Tomicic 1, * , Ruth Meise 1, * , Dorthe Aasland 1 , Nancy Berte 1 , Rebekka Kitzinger 1 , Oliver H. Kramer 1 , Bernd Kaina 1 , Markus Christmann 1 1 Department of Toxicology, University Medical Center Mainz, D-55131 Mainz, Germany * These
Publikováno v:
Anticancer research. 38(9)
Background/aim High expression of the Bcl-2-interacting cell death suppressor (BIS), an anti-apoptotic protein, in various human cancers is linked to a poor outcome. The purpose of this study was to clarify whether BIS is associated with the migratio
Autor:
Liwei Chen, Nicholas J. Lawrence, John M. Koomen, Yuan Ren, Valentina E. Schneeberger, Harshani R. Lawrence, Noreen Luetteke, Domenico Coppola, Eric B. Haura, Jie Wu, Qingling Huang
Publikováno v:
Oncotarget
Epidermal growth factor receptor (EGFR) mutants drive lung tumorigenesis and are targeted for therapy. However, resistance to EGFR inhibitors has been observed, in which the mutant EGFR remains active. Thus, it is important to uncover mediators of EG
Autor:
Hui‑Rong Jing, Ji‑Hong Yao, Shu Wang, Feng Zhang, Wei Xu, Yan Hu, Xiaomei Xu, Shi‑Li Ning, Xiao‑Feng Tian, Zhenlu Li
Publikováno v:
Molecular Medicine Reports. 11:269-276
Acute lung injury (ALI) is a common complication following intestinal ischemia/reperfusion (I/R) and is a major contributing factor to its high mortality rate. Sirtuin 1 (SIRT1), a NAD+-dependent deacetylase, has been reported to have an important ro
Autor:
Warren Fiskus, Manuel Hidalgo, Peter Atadja, Anirban Maitra, Kapil N. Bhalla, Karissa Peth, Sreedhar Venkannagari
Publikováno v:
Oncotarget
// Sreedhar Venkannagari 1 , Warren Fiskus 1 , Karissa Peth 1 , Peter Atadja 2 , Manuel Hidalgo 3 , Anirban Maitra 4 and Kapil N. Bhalla 1 1 The University of Kansas Cancer Center, Kansas City, KS, 2 Novartis Institute for Biomedical Research Inc., C